A 59-year-old man diagnosed with borderline lepromatous leprosy developed reddish patches and plaques on the face, which progressively enlarged and spread to the trunk and limbs ( Figure 1A-D) . Other superficial nerves appeared normal. Biopsy showed plasmocytic and lymphocytic infiltration in the nerve tract, and was 4+ acid-fast bacilli (AFB)-stain positive suggesting Mycobacterium leprae ( Figure 2A and B); this was confirmed by real-time polymerase chain reaction (PCR). The HLA-B*13:01 test was negative. Two weeks after rifampin, dapsone, and clofazimine (World Health Organization multidrug therapy [WHO MDT] regimen) were started, the skin lesions (hypochromic macules) became red, edematous, and enlarged ( Figure 3A-D) . Both ulnar nerves became tender and thickened; ultrasonography showed reduction of blood flow ( Figure 4A and B) . Collectively these findings indicated a type 1 conversion reaction (T1R) ( Figure 2C ). One year after prednisone was started (40 mg/day for 3 months with progressive tapering), the T1R was found to be completely resolved.
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In leprosy, type 1 and type 2 reactions-whether spontaneous or related to treatment-are the main causes of morbidity. T1Rs result from cell-mediated immunity affecting up to 30% of susceptible individuals.
1 Nonpolar forms of leprosy are the primary risk factor for the occurrence of T1Rs.
2 Systemic corticosteroids remain the mainstay of treatment of T1Rs.
